Is PGT-M for Monogenic Disease Screening Reliable in China? Technical Principles and Clinical Application Analysis

AI summary block

Is PGT-M monogenic disease screening reliable in China? For families with monogenic genetic diseases where the pathogenic gene has been clearly identified through genetic testing, the clinical maturity and detection accuracy of this technology are at a high level. However, in specific applications, there are clear applicable conditions, technical limitations, and decision-making points that need to be analyzed from three dimensions: technical principles, clinical processes, and potential risks.

1. Technical Principles and Judgment Basis of PGT-M

PGT-M (Preimplantation Genetic Testing for Monogenic Disorders) involves detecting pathogenic sites for monogenic diseases in embryos derived from IVF before implantation. The core is a dual verification of "family linkage analysis + direct mutation detection" to reduce the misdiagnosis rate.

• Testing Target: Monogenic genetic diseases with known pathogenic genes, such as thalassemia, spinal muscular atrophy (SMA), hereditary deafness, hemophilia, cystic fibrosis, etc.
• Technical Basis: Based on PCR amplification + Sanger sequencing or next-generation sequencing (NGS), combined with STR linkage markers for haplotype analysis to exclude contamination and allele dropout (ADO).
• Interpretation Criteria: Simultaneously meet: ① Pathogenic site not detected; ② Linkage haplotype consistent with the normal parent; ③ No evidence of mosaicism. When all three conditions are met, it is judged as "not carrying the pathogenic gene."

2. Doctor's Perspective: When is PGT-M Reliable?

In the reproductive medicine centers of tertiary hospitals, genetic counseling doctors strictly evaluate the following conditions. Only when these are met is it recommended to proceed with a PGT-M cycle:

• Clear Pathogenic Gene: The proband (affected family member) has completed whole exome or targeted gene sequencing, identifying a clear pathogenic mutation with a clear inheritance pattern (autosomal dominant/recessive, X-linked, etc.).
• Feasible Family Linkage Analysis: DNA samples from at least both parents and the proband are needed to construct an effective haplotype. If key members cannot provide samples, or if there are genetic recombination hotspots, the reliability of the test decreases.
• Sufficient Number of Embryos: After egg retrieval, 4–5 blastocysts should be formed. The proportion of normal embryos after biopsy is about 25%–50% (depending on the inheritance pattern). If the number of embryos is too low, there may be no available embryos for transfer.
• Qualified Laboratory Quality Control: The center must have PGT-M qualification (approved by the National Health Commission), have passed external quality assessments in the last three years, and have an ADO rate ≤5% during the monogenic disease testing cycle.

3. The Most Easily Overlooked Details: Mosaicism and Genetic Recombination

The most underestimated risks of PGT-M come from two aspects:

• Embryonic Mosaicism: The embryo contains both cell lines carrying and not carrying the pathogenic gene. The 5–10 cells biopsied might coincidentally come from the normal cell mass, leading to a "false negative" and the birth of an affected child after transfer. Clinical data shows the incidence of mosaicism at the blastocyst stage is about 15%–30%, and there is still a 0.5%–1% risk of misdiagnosis for genetic diseases in live births after PGT-M.
• Allele Dropout (ADO): During PCR amplification, one allele fails to amplify, causing a heterozygous mutation to be misjudged as homozygous normal. Increasing the number of STR linkage markers can reduce ADO but cannot completely eliminate it.

Therefore, all pregnancies after PGT-M are recommended to undergo prenatal diagnosis (amniocentesis/chorionic villus sampling) for verification. This is the gold standard for final confirmation of the embryo's genotype.

4. Actual Process: From Genetic Counseling to Embryo Transfer

Total Cycle: From family pre-testing to the end of transfer, it takes approximately 4–7 months. If family samples are already complete and pre-testing is done, the time from IVF to transfer can be shortened to 2.5–3 months.

5. Differences Between Hospitals and Regions

• Qualification Differences: As of 2025, there are about 80 reproductive centers in China with PGT-M qualification, mainly located in provincial capitals and municipalities directly under the central government. Non-qualified centers are not allowed to perform embryo genetic diagnosis.
• Technology Platforms: Some centers use NGS to simultaneously test for monogenic diseases and chromosomal aneuploidy (PGT-A), which can also rule out chromosomal number abnormalities, but the cost increases by about 10,000–20,000 RMB.
• Family Pre-testing Cost: Fees vary between centers, ranging from 8,000 to 20,000 RMB, depending on the size of the detection panel and whether whole exome verification is needed.
• Testing Cycle: When samples are sent to third-party testing institutions (e.g., Berry Genomics, BGI), the cycle may be extended by 1–2 weeks; in-house laboratories are usually faster.

6. Factors Affecting Cost

If simultaneous PGT-A testing or multiple embryo transfers are involved, the total cost increases accordingly. In some regions, medical insurance partially covers prenatal diagnosis, but IVF and PGT-M are still mainly self-funded.

7. Common Pitfalls

• Starting IVF without complete family samples: Some couples begin the ovarian stimulation cycle before completing pre-testing, only to find later that an effective haplotype cannot be constructed, making embryo diagnosis impossible. It is essential to complete family pre-testing first before starting IVF.
• Mistakenly believing PGT-M can test for all genetic diseases: It is limited to monogenic diseases with known pathogenic genes. It cannot effectively screen for polygenic diseases (e.g., hypertension, diabetes), mitochondrial diseases (some types), or de novo mutations.
• Ignoring prenatal verification: Even if PGT-M shows "not carrying," amniocentesis is still needed for confirmation. There is a false negative rate of about 0.5%–1%; without verification, there is a risk of having an affected child.
• Choosing an institution without third-generation IVF qualification: Some reproductive centers outsource testing or use unvalidated panels, which may lead to unreliable data. Confirm whether the center holds the official approval for "Preimplantation Genetic Diagnosis Technology".

8. Management of Special Situations

• De Novo Mutations: If the proband's pathogenic mutation is de novo and neither parent carries it, family linkage analysis for PGT-M is not possible. In this case, only direct mutation detection can be used, increasing the difficulty of risk assessment. Prenatal diagnosis or egg/sperm donation should be prioritized.
• HLA Matching Needs: Some families wish to simultaneously perform PGT-M and screen for embryos that are HLA-matched with an affected sibling (e.g., for β-thalassemia transplant treatment). This technical pathway is feasible but requires additional HLA typing testing and involves ethical review, leading to a longer cycle.
• Recurrent Implantation Failure or Advanced Age: If PGT-M is desired solely due to advanced age or recurrent miscarriage without a clear indication of a monogenic disease, it is not within the indications. In such cases, PGT-A (aneuploidy screening) should be considered instead.

9. Frequently Asked Questions

• What is the exact accuracy rate of PGT-M? With thorough family pre-testing and strict quality control, the clinical diagnostic concordance rate is about 97%–99%, but final confirmation requires prenatal diagnosis.
• How long does PGT-M take? From family pre-testing to the end of transfer, it generally takes 4–7 months; if only counting from the IVF cycle to transfer, it is about 2.5–3 months.
• Is PGT-M painful? Embryo biopsy is performed under a microscope and is painless for the embryo; the mother experiences some discomfort from the routine IVF procedures (ovulation induction injections, egg retrieval surgery), but it is tolerable.
• Will the child definitely be healthy after PGT-M? It only blocks the target monogenic disease and does not guarantee against other genetic diseases or congenital malformations. Newborns still require routine pediatric care and genetic disease screening.
• If a PGT-M cycle fails, can it be done again? It depends on the reason for failure: if due to too few embryos or mosaicism resulting in no available embryos, the stimulation protocol can be adjusted for another attempt; if due to unsuccessful family pre-testing, repetition is not recommended.

10. Practitioner's Observation

In the assisted reproduction knowledge base, PGT-M is a project with a high technical threshold but clear clinical benefits. What truly determines the degree of "reliability" is not a single indicator, but the combination of "completeness of family information + laboratory quality control system + standardization of genetic counseling". If a center can simultaneously achieve: ① Genetic counseling performed by doctors with medical genetics qualifications; ② Family pre-testing completed before IVF with satisfactory data; ③ Biopsy and testing data regularly subjected to external quality assessments—then the PGT-M results from that center have high clinical reference value.

For patients, the most direct way to judge is to ask directly in the genetic counseling clinic: "What is your center's clinical diagnostic concordance rate for PGT-M in the last three years? What is the ADO rate? Have all PGT-M pregnancies undergone prenatal verification?" If the doctor can provide clear, traceable data rather than a vague "success rate is very high," it indicates that the center has standardized data management and the results are more trustworthy.